The Lawyer’s new China Elite report contains the most detailed research available on the PRC legal market and contains unparalleled insight into the country's leading law firms. They vary in size, practice focus and geographic coverage, but they all share one common quality – ambition... Read more
This year, The Lawyer’s annual ranking of the largest UK law firms by turnover is available as an interactive, digital benchmarking tool. For the first time this will allow you to manipulate each data set against the metrics of your choice.
New York firms Cravath Swaine & Moore and Cadwalader Wickersham & Taft have both grabbed the top roles on Johnson & Johnson’s $16.6bn acquisition of Pfizer Consumer Healthcare.
Cravath partner George Schoen said old connections helped the firm win its role: “Johnson & Johnson is a long term client of Cravath. It’s a carve-out business deal, and a fairly typical acquisition around the price that the seller expected.”
Cravath corporate partners Robert Townsend and George Schoen will lead Johnson & Johnson through the transaction. Dennis Block and William Mills, partners at Cadwalader, will advise Pfizer Consumer Healthcare.
Pfizer also attracted bids from healthcare companies GlaxoSmithKline, Colgate-Palmolive and Reckitt Benkiser, but selected Johnson & Johnson’s bid.
“My understanding is that it was a competitive situation,” said Schoer.